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Abstract 
 
Background: Although myocardial fibrosis plays an important role in the progression of heart 
failure (HF;心不全), its prognostic impact still remains to be clarified.  Methods and 
Results: I examined consecutive 172 patients with chronic HF, who underwent cardiac 
catheterization and endomyocardial biopsy from January 2001 to September 2008.  I divided 
them into 2 groups; HF with preserved ejection fraction (HFPEF, left ventricular ejection 
fraction (LVEF;左室駆出率) ≥50%, n=81) and HF with reduced LVEF (HFREF, LVEF 
<50%, n=91).  I calculated collagen volume fraction (CVF) in biopsy samples and examined 
its prognostic impact.  Mean follow-up period in the HFPEF and the HFREF group was 
41±33 [SD] and 41±26 months, respectively.  Although the extent of CVF was comparable 
between the 2 groups (1.83±1.54% vs. 2.07±2.35%), CVF was significantly correlated with 
LVEDP in the HFREF group but not in the HFPEF group.  When HF stage was adjusted, the 
long-term prognosis was comparable between the 2 groups.  However, when the patients 
were divided into the 2 groups by the median CVF value, severe fibrosis was a significant 
predictor for all-cause death (P=0.014) and cardiac events (P=0.02) in the HFREF, but not in 
the HFPEF group.  Conclusions: These results indicate that myocardial fibrosis evaluated 
with biopsy samples is a useful predictor for long-term survival, suggesting that it may be an 
important therapeutic target as well. 
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Introduction 
Myocardial extracellular matrix (ECM;細胞外器質) plays important roles to maintain the 
structure of myocytes and blood vessels to strengthen myocardial tissue.
1, 2
  Myocardial 
collagen volume, a major content of ECM, is an important determinant of ventricular 
remodeling that affects ventricular functions.
3
  It has previously been demonstrated that 
myocardial collagen content is correlated with left ventricular (LV;左心室) stiffness in 
patients with heat failure 
4, 5
 and that the extent of myocardial collagen is correlated with a 
reduction in LV ejection fraction (LVEF) and is involved in the process of LV dilatation and 
progression of HF.
6, 7
  Furthermore, the presence of excessive collagen fiber may induce fatal 
ventricular arrhythmia.
8
  Thus, it is important to estimate the extent of myocardial interstitial 
fibrosis in order to predict prognosis of HF patients.   
Cardiovascular magnetic resonance imaging (MRI;磁気共鳴映像法) is a useful tool to 
evaluate myocardial fibrosis that can estimate the prognosis of HF patients by evaluation of 
LV midwall fibrosis using late gadolinium-enhancement.
9
  Indeed, MRI can detect and 
quantify regional myocardial fibrosis in a ventricle but not diffuse myocardial fibrosis.
10
  
Although serum levels of collagen synthesis markers (e.g. procollagen type III 
amino-terminal peptide, PIIINP;プロコラーゲン III-N 末端) may be useful to estimate the 
prognosis of HF patients,
11-13
 those markers may reflect systemic fibrosis.
14, 15
  Indeed, little 
is known about the relation between the prognosis of HF patients and the extent of myocardial 
fibrosis that is directly calculated from biopsy specimens in HF patients.  In the present study, 
I thus examined whether collagen volume fraction (CVF) obtained from LV endmyocardial 
biopsy samples has a prognostic impact in HF patients with or without systolic dysfunction. 
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Methods 
The ethical committees of Tohoku University Hospital approved the study protocol and all 
patients provided written informed consent. 
 
Study Population 
I examined consecutive 172 patients with chronic HF enrolled in our database, who 
hospitalized at our hospital and underwent cardiac catheterization and endomyocardial biopsy 
to diagnose the etiology of HF from January 2001 to September 2008.  Endomyocardial 
biopsy in all HF patients with suspected cardiomyopathy was performed, but not performed in 
those who had apparent ischemic or valvular heart disease documented by echocardiography 
and/or cardiac catheterization.  Inclusion and exclusion criteria are showed in Table 1.  
For each patient, I collected clinical, hemodynamic, biochemistry and prognostic 
data and analyzed myocardial samples obtained by endomyocardial biopsy. 
 
Definition of HF 
In this study, I included the patients in stage B, C and D, according to the ACC/AHA 2005 
guidelines of chronic HF (Figure 1).  According to the ESC 2007 guideline of HF, I also 
divided them into the 2 groups; HFPEF (LVEF≥50%, n=81) and HFREF (LVEF<50, n=91).  
 
Data Collections  
Baseline demographic data, hemodynamic data obtained by catheterization, stage of HF, 
medications and comobidities (hypertension, diabetes mellitus, hyperlipidemia, and atrial 
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fibrillation) were obtained based on their medical records.  The hemodynamic parameters 
measured by cardiac catheterization included LVEF, LV end-diastolic volume index 
(LVEDVI;左室拡張末期容積), mean aortic pressure (mAoP;平均動脈圧), LV end diastolic 
pressure (LVEDP;左室拡張末期圧), mean pulmonary artery pressure (mPAP;平均肺動脈圧), 
pulmonary capillary wedge pressure (PCWP;肺動脈楔入圧) and cardiac index (CI;心係数).  
Before cardiac catheterization, I measured serum levels of hemoglobin, brain natriuretic 
peptide (BNP;脳性ナトリウム利尿ペプチド), creatinine and high-sensitivity C-reactive 
protein (hsCRP;高感度 C 反応性タンパク) and estimated cretinine clearance by 
Cockroft-Gault formula. 
The primary end-points included all-cause death, and secondary combined endpoints 
included cardiovascular death, sudden death and admission for worsening of HF, and 
follow-up data were obtained from our database. 
 
Quantitative Morphometry of Biopsy Samples 
Transvenous endomyocardial biopsy samples were obtained from the interventricular septum 
with 6Fr Biotom (Cordis, Bridgewater, NJ).  There were no major complications related to 
the procedures during the study period.  The tissues were immediately fixed in 10% buffered 
formalin and embedded in paraffin.  Tissue sections were stained with hematoxylin-eosin 
staining and Elastica-Masson staining.  Images of these sections were acquired with a 
projection microscope (x400, Figure 2).  Subsequent image analysis was performed with 
Macscope software 2.5 (Mitani, Fukui, Japan) to determine cardiomyocyte diameter and 
extent of myocardial interstitial fibrosis, which was expressed as collagen volume fraction 
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(CVF, %).  CVF was calculated as the sum of all connective tissue areas divided by the sum 
of all connective tissue and muscle areas averaged over 2 to 5 representative fields of the 
section (mean 3.6±0.9 fields), where there was no endocardium or blood vessel.
16,17
  
Myocardial diameter (MyD;心筋細胞径) was determined at the nucleus level in 
representative 8 to 15 cardiomyocytes (mean 12.0±2.5 fields) per each section, where I also 
counted the number of inflammatory mononuclear cells in the same fields (mean 6.0±1.8).  
These histological evaluations were performed by the well-trained cardiologist without 
knowledge of which patient provided the tissue sections. 
I divided both the HFPEF and HFREF groups into 2 groups using each median CVF 
value (HFPEF and HFREF; 1.36% and 1.34%).  I defined the mild and severe fibrosis 
groups when CVF was smaller and greater than the median value, respectively, as shown in 
Figure 1. 
 
Statistical analysis 
Continuous variables are expressed as mean±SD.  Comparisons between 2 groups were 
conducted with unpaired t-test for continuous variables and chi-test for categorical variables.    
Five-year survival free from all-cause death and that from cardiac events were estimated by 
Kaplan-Meier method.  I used Cox proportional-hazards model to adjust covariates.  After 
comparison of covariates between the mild and severe fibrosis groups, the covariates for 
which P was less than 0.05 were applied to final multivariate models.  Furthermore, I 
evaluated the prognostic value of CVF as a continuous variable.  I applied the variables for 
which P value was less than 0.05 in the univariate analyses to final multivariate models, 
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where age, CI, LV filling pressure, and stage of HF were applied to adjustment, and I chose 
the parameters for final models using step-up method.  In these analyses, I used PCWP as a 
parameter of LV filling pressure, because the data of LVEDP were lacking in 3 cases.  
Furthermore, as previously reported,
16
 I tested the proportionality assumptions of each 
parameter of the final models, with a P-value of <0.05 indicating non-proportionality.  All 
statistical analyses were performed using JMP 7.0.2 (SAS Institute, Cary, NC) and R 
2.8.1(www.r-project.org/).  All P values were 2-sided, and P values of less than 0.05 were 
considered to be statistically significant. 
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Results 
Comparison between the HFPEF and the HFREF Groups 
All patients were successfully followed-up in the present study.  Mean follow-up period in 
the HFPEF and the HFREF group was 41±33 [SD] and 41±26 months, respectively.  The 
HFREF group was characterized by more advanced stages of HF (Table 2).  There were 
more all-cause deaths and cardiac events in the HFREF group than in the HFPEF group 
(Table 2).  Five-year prognosis was significantly lower in the HFREF group than in the 
HFPEF group, in terms of survival from all-cause death (P=0.006) and survival from cardiac 
events (P=0.034).  However, after the adjustment of HF stage of HF, there was no significant 
difference in cardiac events between the 2 groups.  
The prevalence of the use of medications for HF at the cardiac catheterization, including 
angiotensin-converting enzyme inhibitors (ACEI;アンギオテンシン変換酵素阻害薬), 
anigiotensin recepter blockers (ARB;アンギオテンシン受容体拮抗薬), -blockers, 
diuretics, spironolactone and digitalis, was significantly higher in the HFREF than in the 
HFPEF group (Table 2).  In contrast, the use of calcium cannel blockers (CCB;カルシウム
拮抗薬) was more common in the HFPEF group (Table 2).  The HFREF group had 
significantly larger LV volume, lower LVEF and lower cardiac index compared with the 
HFPEF group (Table 2).  Although LVEDP and CVF were comparable between the 2 groups 
(Table 2), CVF was significantly correlated with LVEDP as well as after adjustment with left 
ventricular peak systolic pressure (LVPSP;左室収縮期圧) in the HFREF group (Figure 3A. 
and 3C), but not in the HFPEF group (Figure 3B and 3C). 
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Morphometric Variables as Prognostic Predictors 
When comparing the mild and the severe fibrosis groups, a statistically significant difference 
was noted in terms of LVEDVI and BNP in the HFREF group (Table 3), but not in the HFPEF 
group (Table 3). 
In the HFREF group, CVF was significantly higher in HF patients who died than in 
survivors (Figure 3A).  Indeed, there were more all-cause deaths and cardiac events in the 
severe fibrosis group than in the mild fibrosis groups (Table 3).  Five-year survival from 
all-cause death was significantly lower in the severe fibrosis group than in the mild fibrosis 
group (mild fibrosis group vs. severe fibrosis group; 95.0% vs. 71.2%, P=0.004) (Figure 4B), 
and was so even after adjustment with the covariate (severe fibrosis vs. mild fibrosis; Hazard 
Ratio (HR;ハザード比) 13.5, 95% CI 2.01-307, P=0.006).  Similarly, survival from cardiac 
events was significantly lower in the severe fibrosis group than in the mild fibrosis group in 
the HFREF (mild fibrosis group vs. severe fibrosis group; 90.5% vs. 58.6%, P=0.003) (Figure 
4C), and was so even after adjustment with the covariate (severe fibrosis vs. mild fibrosis; HR 
6.20, 95% CI 1.52-25.4, P=0.011).  In contrast, in the HFPEF group, there was no significant 
difference in the cardiac events (Table 2) or survival rate (Figure 4D) between the mild and 
severe fibrosis groups (mild fibrosis group vs. severe fibrosis group; 93.8% vs. 89.8%, 
P=0.645).  In the HFREF group, multivariate analysis showed that a 1% elevation of CVF 
increased the risk of all-cause death and that of cardiac events by 1.50-fold (95% CI 1.18-1.95, 
P=0.002) and 1.28-fold (95% CI 1.07-1.50, P=0.008), respectively (Figure 5).  Furthermore, 
other histological parameters (e.g. cardiomyocyte hypertrophy) were not significant predictors 
in the present study.   
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Discussion 
The novel findings of the present study are as follows; (1) CVF was comparable between the 
HFPEF and HFREF groups, (2) CVF was an independent predictor of all-cause death and 
cardiac events in the HFREF group but not in the HFPEF, and (3) CVF was significantly 
correlated with LVEDP in the HFREF group but not in the HFPEF group.  To the best of our 
knowledge, this is the first report that demonstrates the prognostic impact of CVF in 
non-ischemic HF patients with systolic dysfunction.  
 
Comparison between the HFPEF and the HFREF Groups 
Several studies have shown that the prognosis is comparable between patients with HFPEF 
and those with HFREF.
17-19
  In the present study, the patients with HFPEF had a significantly 
better prognosis than those with HFREF; however, after the adjustment with stage of HF, the 
survival became comparable between the 2 groups.  In the present study, the 5-year survival 
rate from all-cause death was apparently better than in the previous study,
20
 probably because 
we monthly followed up the patients to control sodium intake and blood pressure.  It has 
been reported that intensive medical treatment for HF patients with close follow-up can 
reduce re-admission for HF and cardiac deaths,
21
 suggesting that our regular follow-up is 
effective to improve the prognosis of the HF patients. 
 
Morphometric Variables and Cardiac Functions as Prognostic Predictors  
Myocardial fibrillar collagen, a main component of ECM, is a major contributor to 
myocardial stiffness.
3
  In the present study, CVF in the HFPEF and the HFREF groups was 
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1.83% and 2.07%, respectively, a consistent finding with the previous report.
22
 
Recently, the degradation of interstitial collagen has been reported in patients with mild 
to moderate dilated cardiomyopathy (DCM;拡張型心筋症).23, 24  In contrast, marked 
accumulation of myocardial interstitial fibrosis has also been reported in patients with 
end-stage HFREF (e.g. explanted heart).
25
  The present study also demonstrated that CVF 
was significantly higher in HF patients who died than in survivors and that CVF and LVEDP 
were significantly correlated in HFREF patients.  Taken together, these results suggest that 
the reduced myocardial interstitial collagen causes LV dilatation as complicated with systolic 
dysfunction in the early stage of HFREF and that the increased myocardial interstitial 
collagen causes diastolic dysfunction in the advanced stage of HFREF with a resultant poor 
prognosis. 
    Although cardiac MRI is well established method to evaluate cardiac fibrosis, it can not 
detect all severe fibrosis cases, especially HFREF patients with non-ischemic etiology.
26
  It 
also has been reported that cardiac MRI can hardly detect diffuse cardiac fibrosis.
27
  
Furthermore, the recent study has demonstrated that late gadolinium enhancement does not 
always indicate the change in myocardial interstitium.
28
  Our preliminary data showed that 
there was no significant difference in CVF between the patients with and those without 
delayed enhancement in cardiac MRI (unpublished observation).  Thus, I consider that I 
should evaluate the extent of myocardial fibrosis in multiple ways, including endomyocardial 
biopsy, MRI and serum markers of collagen turnover. 
It was reported that HFREF patients with diastolic dysfunction had a worse prognosis 
than those without it.
29, 30
  In the present study, elevated LVEDP was significantly related to 
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the increased CVF.  Therefore, accumulation of myocardial interstitial fibrillar collagen may 
cause ventricular diastolic dysfunction in the HFREF group with a resultant poor prognosis.  
The Randomized Aldactone Evaluation Study (RALES) showed that spironolactone improves 
the prognosis in HF patients.
31
  Interestingly, the RALES subanalysis showed that this 
benefit of spironolactone is noted only in patients with high-level of PIIINP but not in those 
with low-level of PIIINP.
11, 31
  It also was demonstrated that spironolactone improved LV 
diastolic dysfunction only in DCM patients with increased myocardial fibrosis.
32
  The 
relation between worsening HF and myocardial fibrosis was shown in Figure 6.  Because 
CVF is a significant predictor even in multivariate analysis with established prognostic 
parameters for HF, it might be useful to predict prognosis of HF patients. 
In contrast, HFPEF seems to be a quite different condition from HFREF in terms of the 
responses to medical treatment.  Although ARBs and ACEIs could decrease myocardial 
fibrosis in HFPEF,
4, 33, 34
 the large clinical trials failed to demonstrate any beneficial effects of 
ARBs or ACEIs (e.g. irbesartan, candesartan, enalapril, and valsartan) in patients with 
HFPEF.
35-38
  This is consistent with the present finding that no significant correlation was 
noted between myocardial fibrosis and cardiac events in the HFPEF group, suggesting that the 
prognostic impact of myocardial fibrosis might be small in HFPEF.  However, it has been 
previouly reported that in approximately 20% of patients with HFPEF, LVEF was 
significantly decreased during the 3 month follow-up period,
39
 a consistent finding with the 
present study, where LVEF was significantly decreased in 11% of patients with HFPEF during 
follow-up.  Thus, patients with severe myocardial fibrosis should be closely followed up 
because HFPEF patients with large CVF are at higher risk for disease progression and poor 
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prognosis.  
 
CVF and LVEDP 
In the present study, a significant but relatively weak correlation was noted between CVF and 
LVEDP in the HFREF group, probably because 60~70 percent of the HFREF patients 
received -blocker and ACEI and/or ARB, which might have affected the systemic 
hemodynamics measured during cardiac catheterization.   
As mentioned above, I was unable to observe any significant correlation between 
CVF and LVEDP in the HFPEF group, probably because the HFPEF group consists of 
heterogeneous disease, such as hypertensive heart disease, cardiac amyloidosis, early-stage 
dilated cardiomyopathy and hypertrophic cardiomyopathy, in addition to the medical 
treatment including -blocker and ACEI and/or ARB. 
 
Study Limitations 
Several limitations should be mentioned for the present study.  First, I only assessed the 
collagen content in the myocardium.  It was previously reported that not only the quantity 
but also the quality of collagen are important determinants for myocardial stiffness.
40
  Indeed, 
the ratio of cross-linked collagen (insoluble collagen) to non-cross-linked collagen (soluble 
collagen) and the type I/type III collagen ratio are important determinants of myocardial 
stiffness,
25, 41, 42
 and reduction in collagen cross-linking ameliorates myocardial stiffness and 
ventricular dilatation irrespective of collagen content.
43
  Although I did not measure collagen 
turnover markers that have been established as prognostic values in HF patients, it has been 
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reported that there is a significant correlation between CVF and procollagen I 
carboxy-terminal peptide (PICP;プロコラーゲン I-C 末端), a collagen synthesis marker.44  
Thus, the quality of ventricular fibrosis should be evaluated in biopsy specimens in future 
studies.  Furthermore, morbidity periods of HF by the time of biopsies might be important 
for the development of myocardial fibrosis; however, no data was available regarding the 
periods in the present study. 
Second, because myocardial fibrosis may exist in a patchy fashion, I obtained at least 3 
endomyocardial biopsy samples in a patient and evaluated CVF in as many fields as possible 
(mean 3.6±0.9 fields) in order to minimize errors from patchy distribution of myocardial 
fibrosis in the present study.  Also, it has been reported that CVF calculated from biopsy 
samples were significantly related with markers of collagen turnover, which might reflect 
degree of fibrosis of whole hearts.
32
  Furthermore, I did not assess inter-rater agreement and 
intra-rater agreement of the software.  I still consider that I should evaluate the extent of 
myocardial fibrosis in multiple ways, including endomyocardial biopsy, MRI and serum 
markers of collagen turnover.   
Third, in the present study, the HF population might be biased because I included the 
patients who underwent endomyocardial biopsy alone and excluded those with other major 
causes of HF, such as ischemic heart disease and valvular heart disease.  However, since I 
did not include HF patients with valvular or ischemic etiology, I was able to minimize the 
overestimation of LVEF due to those factors in the present study. 
Forth, the present study was an observational study with a relatively small number of 
patients and for ethical reason, I was unable to perform repetitive myocardial biopsy to 
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evaluate the time-course of HF.  Thus, a future study with a large number of patients with a 
longer follow-up is required to address this issue. 
Finally, the relatively small number of events limits the generalization of the present 
findings.  Although I analyzed the present results with several statistical models, I found that 
the Cox proportional hazard model was the best to analyze the present results.  Thus, after 
univariate analyses, I used the Cox proportional hazard model with as small covariates as 
possible. 
 
In conclusion, I was able to demonstrate that myocardial CVF evaluated with biopsy samples 
is a useful predictor for long-term survival in patients with HFREF (but not in those with 
HFPEF) and may be an important therapeutic target as well.  
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Figure 1. Stages in the Development of Heart Failure 
HF=heart failure 
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Figure 2. Representative Histology of the Mild and Severe Fibrosis Groups 
Myocardial fibrosis, stained in blue by Elastica-Masson staining (left; mild fibrosis, right; 
severe fibrosis).  
CVF=collagen volume fraction. Scale bar, 50 m.  
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Figure 3. Correlation between CVF and LVEDP 
A significant correlation was noted between CVF and LVEDP for patients with HFREF 
(r=0.387, P<0.001) (A) but not for those with HFPEF (r=-0.092, P=0.664) (B).  
LVEDP/LVPSP ratio and CVF were also significantly correlated in the HFREF group 
(r=0.515, P<0.001) (C), but not in the HFPEF group (r=-0.097, P=0.393) (D). 
CVF=collagen volume fraction, LVEDP=left ventricular end-diastolic pressure, LVPSP=left 
ventricular peak systolic pressure.  
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Figure 4. Comparison of Survival between the Mild and the Severe Fibrosis Groups 
(A) CVF was significantly higher in HF patients who died than in survivors.  (B, C) The 
mild fibrosis group showed better survival from all-cause death (B) and that from cardiac 
events compared with the severe fibrosis group.  (D) In contrast, no difference was noted 
between the mils and severe fibrosis groups. 
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Figure 5. Hazard Ratio of All-cause Death and Cardiac Event  
(A, B) In the HFREF group, PCWP and CVF were significant independent predictors of 
all-cause death (A) and cardiac events (B).  
CI=cardiac index, HR=hazard ratio, PCWP=pulmonary capillary wedge pressure, 95% 
CI=95% confidential interval. 
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Figure 6. The Relation between Worsening HF and Myocardial Fibrosis 
HF=heart failure, RAAS=renin-angiotensin-aldosterone system
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Table 1.  Inclusion and Exclusion Criteria 
Inclusion criteria Exclusion criteria 
Chronic HF of stage B, C or D Valvular heart disease 
Patients who underwent endomyocardial biopsy Coronary heart disease 
Unknown etiology of HF 
 
HF=heart failure 
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Table 2. Baseline Characteristics of the HFPEF and the HFREF Groups 
 HFPEF HFREF P value 
 (n=81) (n=91)  
Age (years old) 54.3 (14.1) 55.9 (12.8) 0.429  
BMI (kg/m
2
) 23.4 (4.5) 23.9 (4.2) 0.408  
Male 54 (67) 66 (73) 0.404  
Hypertension 34 (42) 39 (43) 0.962  
Diabetes mellitus 9 (11) 13 (14) 0.533  
Dyslipidemia 21 (26) 21 (23) 0.631  
Sinus rhythm 69 (85) 65 (71) 0.028
*
 
Medication    
 ACEI 36 (44) 57 (63) 0.017
*
 
 ARB 15 (19) 35 (38) 0.004
*
 
 β-blocker 39 (48) 66 (73) 0.001* 
 Diuretics 13 (16) 41 (45) <0.001
*
 
 Spironolactone 10 (12) 31 (34) 0.001
*
 
 Warfarin 12 (15) 46 (51) <0.001
*
 
 Digitalis 7 (9) 28 (31) <0.001
*
 
 CCB 26 (32) 11 (12) 0.001
*
 
 Antiplatelet 13 (16) 27 (30) 0.033
*
 
 Statin 7 (9) 17 (19) 0.054  
 Amiodarone 5 (6) 8 (9) 0.514  
Stage of heart failure   <0.001
*
 
 B 40 (49) 15 (16)  
 C 39 (48) 68 (75)  
 D 2 (2) 8 (9)  
   
Laboratory data    
 Hemoglobin (g/dl) 13.8 (2.0) 14.1 (1.8) 0.277  
 hsCRP (mg/dl) 0.21 (0.46) 0.33 (0.93) 0.294  
 BNP (pg/ml) 248 (342) 367 (491) 0.089  
 LDL (mg/dl) 110 (41) 121 (39) 0.103  
 HDL (mg/dl) 54.9 (24.0) 45.1 (12.8) 0.001
*
 
 TG (mg/dl) 131 (98) 137 (75) 0.669  
 Glucose mg/dl) 106 (37) 106 (21) 0.934  
 Ccr (ml/min) 90.1 (25.1) 88.2 (35.4) 0.694  
Hemodynamic data    
 LVEDVI (ml/m
2
) 75.7 (20.4) 114.5 (35.1) <0.001
*
 
 EF (%) 67.8 (11.3) 35.6 (11.0) <0.001
*
 
 mAoP (mmHg) 96 (15) 90 (17) 0.023
*
 
 LVEDP (mmHg) 14 (6) 13 (7) 0.420  
 mPAP (mmHg) 16.7 (4.8) 19.9 (7.7) 0.002
*
 
 PCWP (mmHg) 9.5 (4.2) 11.2 (6.5) 0.050 
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 CI (L/min/m
2
) 2.9 (0.7) 2.6 (0.7) 0.021
*
 
Morphometric data    
 CVF (%) 1.83 (1.54) 2.07 (2.35) 0.440  
 MyD (micrometer) 19.2 (3.2) 19.7 (2.8) 0.362  
 Inflammatory cell (/field) 4.9 (4.9) 7.0 (6.0) 0.015
*
 
All-cause death 0 (0) 9 (10) 0.004
*
 
Cardiac events 4 (5) 15 (16) 0.016
*
 
 Cardiac or Sudden death 0 (0) 4 (4)  
 Admission for HF 4 (5) 11 (12)  
Continuous and categorical variables are presented as mean (SD) and n (percentage), 
respectively.  *P<0.05, HFPEF vs. HFREF.   
ACEI=angiotensin-converting enzyme inhibitor, ARB=anigiotensin recepter blocker, 
BMI=body mass index, BNP=brain natriuretic peptide, CCB=calcium cannel blocker, 
CCr=creatinine clearance, CI=cardiac index, CVF=collagen volume fraction, EF=ejection 
fraction, hsCRP=high-sensitivity C-reacting protein, LVEDVI=left ventricular end-diastolic 
volume index, LVEDP=left ventricular end diastolic pressure, mAoP=mean aortic pressure, 
mPAP=mean pulmonary artery pressure, MyD=cardiomyocyte diameter, PCWP=pulmonary 
capillary wedge pressure 
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Table 3. Comparison between Mild and Severe Fibrosis Group in the HFREF and HFPEF Groups 
    HFPEF HFREF 
  
Mild 
fibrosis 
Severe 
fibrosis 
P value 
Mild 
fibrosis 
Severe 
fibrosis 
P value 
  (n=40) (n=41)   (n=46) (n=45)   
Age (years old) 57 (11) 52 (16) 0.082 58 (12) 54 (14) 0.21 
BMI (kg/m
2
) 23 (5) 23 (4) 0.96 24 (4) 24 (4) 0.372 
Male 29 (73) 25 (63) 0.238 34 (74) 32 (70) 0.949 
Hypertension 13 (33) 21 (53) 0.164 21 (46) 18 (39) 0.739 
Diabetes mellitus 5 (13) 4 (10) 0.906 5 (11) 8 (17) 0.521 
Dyslipidemia 10 (25) 11 (28) 0.894 12 (26) 9 (20) 0.66 
Sinus rhythm 31 (78) 38 (93) 0.281 31 (67) 34 (76) 0.389 
Medication       
 ACEI 17 (43) 19 (48) 0.941 28 (61) 29 (63) 0.892 
 ARB 7 (18) 8 (20) 0.874 18 (39) 17 (37) 0.934 
 β-blocker 19 (48) 20 (50) 0.902 32 (70) 34 (74) 0.685 
 Diuretics 7 (18) 6 (15) 0.884 17 (37) 24 (52) 0.174 
 Spironolactone 7 (18) 3 (8) 0.255 16 (35) 15 (33) 0.94 
 Warfarin 5 (13) 7 (18) 0.862 20 (43) 26 (57) 0.248 
 Digitalis 5 (13) 2 (5) 0.371 17 (37) 11 (24) 0.287 
 CCB 14 (35) 12 (30) 0.64 6 (13) 5 (11) 0.969 
 Antiplatelet 6 (15) 7 (18) 0.884 14 (30) 13 (28) 0.946 
 Statin 2 (5) 5 (13) 0.491 8 (17) 9 (20) 0.96 
 Amiodarone 5 (13) 0 (0) 0.053 3 (7) 5 (11) 0.687 
Stage of heart failure   0.236   0.577 
 B 23 (58) 17 (43)  9 (20) 6 (13)  
 C 16 (40) 23 (58)  34 (74) 34 (74)  
 D 1 (3) 1 (3)  3 (7) 5 (11)  
       
Laboratory data       
 Hemoglobin (g/dl) 14 (2) 14 (2) 0.357 14 (2) 14 (2) 0.674 
 hsCRP (mg/dl) 0.16 (0.29) 0.26 (0.58) 0.317 0.35 (1.12) 0.32 (0.69) 0.888 
 BNP (pg/ml) 255 (377) 243 (314) 0.892 245 (347) 494 (584) 0.019
*
  
 LDL (mg/dl) 108 (38) 113 (44) 0.635 116 (38) 125 (40) 0.239 
 HDL (mg/dl) 52 (21) 58 (26) 0.269 45 (14) 45 (11) 0.952 
 TG (mg/dl) 125 (75) 137 (116) 0.603 145 (86) 129 (62) 0.305 
 Glucose mg/dl) 112 (43) 100 (29) 0.134 104 (19) 109 (23) 0.315 
 Ccr (ml/min) 90 (25) 90 (26) 0.898 89 (30) 87 (40) 0.804 
Hemodynamic data       
 LVEDVI (ml/m
2
) 76 (18) 75 (22) 0.874 107 (28) 122 (40) 0.040
*
  
 EF (%) 66 (11) 69 (11) 0.275 38 (11) 33 (11) 0.053 
 mAoP (mmHg) 97 (16) 96 (15) 0.775 92 (15) 88 (19) 0.189 
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 LVEDP (mmHg) 14 (7) 13 (6) 0.236 11 (6) 14 (8) 0.06 
 mPAP (mmHg) 17 (4) 17 (5) 0.736 19 (7) 21 (9) 0.136 
 PCWP (mmHg) 10 (4) 9 (4) 0.926 10 (5) 12 (8) 0.161 
 CI (L/min/m
2
) 2.9 (0.7) 2.9 (0.7) 0.932 2.7 (0.7) 2.6 (0.6) 0.367 
Morphometric data       
 CVF (%) 0.64 (0.41) 2.93 (1.38) <0.001
*
  0.61 (0.4) 3.56 (2.58) <0.001
*
  
 MyD (micrometer) 19 (1.9) 20 (4.1) 0.287 19 (2) 20 (3) 0.055 
 Inflammatory cell (/field) 4.7 (4.6) 5.1 (5.2) 0.696 8 (6) 6 (6) 0.116 
All-cause death 0 (0) 0 (0) - 1 (2) 8 (18) 0.013
*
 
Cardiac events 3 (8) 1 (2) 0.293 3 (7) 12 (27) 0.001
*
 
 Cardiac or Sudden death 0 (0) 0 (0)  1 (2) 3 (7)  
  Admission for HF 3 (8) 1 (2)   2 (4) 9 (20)   
Abbreviations: see Table 1. 
 
*P<0.05, mild fibrosis vs. severe fibrosis.  
 
 
